XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Aug. 20, 2019
Mar. 31, 2022
Feb. 28, 2022
Feb. 28, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Sale Of Stock [Line Items]              
Common stock, shares authorized   100,000,000     100,000,000   100,000,000
Common stock, par value   $ 0.001     $ 0.001   $ 0.001
Preferred stock, shares authorized   5,000,000     5,000,000   5,000,000
Preferred stock, par value   $ 0.001     $ 0.001   $ 0.001
Common stock, shares outstanding   53,591,225     53,591,225   53,480,812
Common stock, shares issued   53,591,225     53,591,225   53,480,812
Preferred stock, shares issued   0     0   0
Preferred Stock Shares Outstanding   0     0   0
Non-Exclusive License Agreement | Enteris Biopharma, Inc. [Member]              
Sale Of Stock [Line Items]              
Upfront fee payment, cash $ 4,000            
Upfront fee payment, stock $ 4,000            
Maximum [Member]              
Sale Of Stock [Line Items]              
Aggregate offering price of securities   $ 300,000     $ 300,000    
Unsold Securities Under Shelf Registration Statement dated April 4, 2019 [Member]              
Sale Of Stock [Line Items]              
Aggregate offering price of securities   154,525     154,525    
Open Market Sales Agreement [Member] | Jeffries LLC [Member]              
Sale Of Stock [Line Items]              
Aggregate offering price of securities   $ 80,000     $ 80,000    
Stock Sale Commission Percentage   3.00%          
Common Stock              
Sale Of Stock [Line Items]              
Restricted stock units vested shares         109,943 109,419  
Restricted Stock Units [Member] | General and Administrative [Member]              
Sale Of Stock [Line Items]              
Compensation expense         $ 1,452 $ 822  
Restricted Stock Units [Member] | General and Administrative [Member] | Director [Member]              
Sale Of Stock [Line Items]              
Compensation expense         $ 139 $ 139  
Performance Restricted Stock Units [Member] | Common Stock | Executive Officers [Member] | March 2022 [Member]              
Sale Of Stock [Line Items]              
Vesting period of awards granted   3 years          
Restricted stock units, vested   37,999          
Performance Restricted Stock Units [Member] | Common Stock | Executive Officers [Member] | February and March 2021 [Member]              
Sale Of Stock [Line Items]              
Restricted stock units vested shares         76,750    
Time-based Restricted Stock Units [Member] | Common Stock | Executive Officers [Member] | March 2022 [Member]              
Sale Of Stock [Line Items]              
Restricted stock units vested shares   39,278          
Time-based Restricted Stock Units [Member] | Common Stock | Executive Officers [Member] | February 2022 [Member]              
Sale Of Stock [Line Items]              
Vesting period of awards granted     3 years        
Restricted stock units vested shares     32,666        
Time-based Restricted Stock Units [Member] | Common Stock | Executive Officers [Member] | February 2021 [Member]              
Sale Of Stock [Line Items]              
Vesting period of awards granted       3 years      
Restricted stock units vested shares       32,669